Zobrazeno 1 - 10
of 2 944
pro vyhledávání: '"LUAD"'
Publikováno v:
World Journal of Surgical Oncology, Vol 22, Iss 1, Pp 1-16 (2024)
Abstract Background Ficolins (FCNs) are a family of proteins, comprising FCN1, FCN2 and FCN3, and integral to the immune system which have been implicated in the onset and progression of tumors. Despite their recognized roles, a comprehensive analysi
Externí odkaz:
https://doaj.org/article/f1bbcfad4d13461ca87b8226b93345da
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-15 (2024)
Abstract Background Lung cancer (LC) occupies an important position in the lethality of cancer patients. Acquired resistance to gefitinib in lung adenocarcinoma (LUAD) seriously affects the therapeutic efficacy of LC. Thus, it is of major scientific
Externí odkaz:
https://doaj.org/article/efd66da8c3fb482c89b4d924219f7afc
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-17 (2024)
Abstract Background Lung cancer is the most common cause of cancer-related death worldwide. The most prevalent histological subtype of lung cancer is lung adenocarcinoma (LUAD), with incidence rising each year. Treating LUAD remains a significant iss
Externí odkaz:
https://doaj.org/article/50e1f58be45549298b85b3b03a7d389d
Autor:
Suet Kee Loo, Gabriel Sica, Xian Wang, Tingting Li, Luping Chen, Autumn Gaither-Davis, Yufei Huang, Timothy F. Burns, Laura P. Stabile, Shou-Jiang Gao
Publikováno v:
Cell & Bioscience, Vol 14, Iss 1, Pp 1-14 (2024)
Abstract Background Lung cancer, a leading global cause of cancer-related mortality, necessitates enhanced prognostic markers for improved treatment outcomes. We have previously shown a tumor suppressive role of cytosolic arginine sensor for mTORC1 s
Externí odkaz:
https://doaj.org/article/acd6b3c9b3c7486ca1dd6bfc35c3d602
Autor:
Pengyu Geng, Fei Ye, Peng Dou, Chunxiu Hu, Jiarui He, Jinhui Zhao, Qi Li, Miao Bao, Xiangnan Li, Xinyu Liu, Guowang Xu
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 43, Iss 1, Pp 1-14 (2024)
Abstract Background The mutations of oncogenic epidermal growth factor receptor (EGFR) is an important cause of lung adenocarcinoma (LUAD) malignance. It has been knowm that metabolic reprogramming is an important hallmark of malignant tumors, and pu
Externí odkaz:
https://doaj.org/article/45faf18145df4198aa60bc3011df6119
Autor:
Xingzhao Ji, Tianyi Zhang, Jian Sun, Xiaojia Song, Guoyuan Ma, Li Xu, Xueru Cao, yongjian jing, Fuyuan Xue, Weiying Zhang, Shengnan Sun, Qiang Wan, Yi Liu
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 43, Iss 1, Pp 1-24 (2024)
Abstract Background Metabolic reprogramming plays a pivotal role in tumorigenesis and development of lung adenocarcinoma (LUAD). However, the precise mechanisms and potential targets for metabolic reprogramming in LUAD remain elusive. Our prior inves
Externí odkaz:
https://doaj.org/article/6362f984034a44eba6bd026786cc7648
Autor:
Zhoulin Miao, Weijie Yu
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-13 (2024)
Abstract Lung adenocarcinoma (LUAD) is the dominant histotype of non-small cell lung cancer. Panoptosis, a comprehensive form of programmed cell death, is central to carcinogenesis. In this study, the expression of PANoptosis-related genes (PRGs) and
Externí odkaz:
https://doaj.org/article/a51bff4ed06845f8af92788b35334036
Publikováno v:
Cancer Cell International, Vol 24, Iss 1, Pp 1-15 (2024)
Abstract Background Phosphofructokinase P (PFKP) is a key rate-limiting enzyme in glycolysis, playing a crucial role in various pathophysiological processes. However, its specific function in tumors remains unclear. This study aims to evaluate the ex
Externí odkaz:
https://doaj.org/article/3dae11f0cb6e436da58c388bc51ee653
Publikováno v:
BioData Mining, Vol 17, Iss 1, Pp 1-14 (2024)
Abstract Background Identifying critical genes is important for understanding the pathogenesis of complex diseases. Traditional studies typically comparing the change of biomecules between normal and disease samples or detecting important vertices fr
Externí odkaz:
https://doaj.org/article/a60df1c17ec14d468080967b8cf4b45a
Autor:
Hong Guo, Doctor of Medicine (M.D.), Guole Nie, Doctor of Medicine (M.D.), Xin Zhao, Master of Medicine (M.M.), Jialu Liu, Master of Medicine (M.M.), Kaihua Yu, Master of Medicine (M.M.), Yulan Li, Doctor of Medicine (M.D.)
Publikováno v:
Surgery Open Science, Vol 22, Iss , Pp 13-23 (2024)
Background: Non-small cell lung cancer (NSCLC) accounts for 85 % of lung cancer cases. Among NSCLC subtypes, lung adenocarcinoma (LUAD) stands as the most prevalent. Regrettably, LUAD continues to exhibit a notably unfavorable overall prognosis. This
Externí odkaz:
https://doaj.org/article/39b2944778d943ccb4ac128dc1d72101